Tag: HEA BIO MTC

Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea

Series A funding to advance MOS118 through Phase 2 clinical trials Biotech veteran David Weber appointed CEO to drive clinical development Obstructive sleep apnea affects nearly...

WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu

The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches...

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia...

SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and...

Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities

BEIJING, June 4, 2025 /PRNewswire/ -- Tsingke Biotech recently participated in TIDES USA 2025, the leading international event for oligonucleotide and peptide therapeutics, held in...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsHEA BIO MTC

Digital Realty Launches Malaysia Operations to Advance Southeast Asia’s Digital Connectivity

Clear Robotics Lands $1.75M to Build the World’s Largest Fleet of Zero-Emission Autonomous Ships

A New Lease of Life: Stories of Hope, Survivorship and Second Chances with Apollo Hospitals

Tag: HEA BIO MTC

Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea

WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia...

Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us